Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Champions Oncology
Hackensack, New Jersey, United Stateschampionsoncology.com ↗
- Ownership
- Public · CSBR
- Employees
- ~210
- Development stage
- Other
01
Overview
Champions Oncology does not develop its own therapeutics but provides industry-leading patient-derived xenograft (PDX) models, advanced analytics, and bioinformatics to accelerate oncology drug development. Their TumorGraft technology has demonstrated high predictive value for clinical outcomes in cancer patients. The company recently expanded into radiotherapeutic studies with an in-house radioactive materials license.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesMonoclonal antibodies (mAbs)Antibody-radionuclide conjugatesPeptide receptor radionuclidesCell therapies (supported in preclinical models)
- Industry
- Drug Discovery Services
02
Partnerships
03
Financials
- Market cap
- $66.3M
- Total revenue
- $59.4M
- Enterprise value
- $72.9M
Beyond the preview
Go deeper on Champions Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Champions Oncology.